Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer

Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

(2010) D. Slamon et al.   CANCER RESEARCH

Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.

(2010) E. Perez et al.   CANCER RESEARCH

Health economics in drug development: Efficient research to inform healthcare funding decisions

(2010) Peter S. Hall et al.   EUROPEAN JOURNAL OF CANCER

Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT)

(2009) A. Niwinska et al.   ANNALS OF ONCOLOGY

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

(2009) L. Gianni et al.   BREAST

The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model

(2009) G. H. de Bock et al.   BREAST CANCER RESEARCH AND TREATMENT

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

(2009) A L Jones et al.   BRITISH JOURNAL OF CANCER

An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial

(2009) Paula K. Lorgelly et al.   EUROPEAN JOURNAL OF HEART FAILURE

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial

(2009) Chris Skedgel et al.   VALUE IN HEALTH

Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer

(2009) Shelby D. Reed et al.   VALUE IN HEALTH

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY

Current perspective – Trastuzumab

(2008) Peter S. Hall et al.   EUROPEAN JOURNAL OF CANCER

Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium

(2008) Mattias Neyt et al.   HEALTH POLICY

Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

(2008) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab

(2008) Kate McKeage et al.   PHARMACOECONOMICS

Is trastuzumab a cost-effective treatment for breast cancer?

(2008) Tallal Younis et al.   Expert Review of Pharmacoeconomics & Outcomes Research